Gilead Sciences

News

miraculous magic pill on a black background

Digital pill tracks HIV PrEP adherence with 98% accuracy

A digital pill that records when it is taken has been shown to be highly effective at helping patients adhere to pre-exposure prophylaxis (PrEP) treatment used to protect them from contract

News

AZ, Daiichi take aim at Gilead in triple-negative breast can...

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete

News

Merck halts more trials of HIV candidate islatravir

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy.

News

Hepatitis Virus - 3d rendered illustration

Gilead files first hepatitis delta therapy with FDA

Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA.

News

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Gilead Sciences' Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a reg

News